Acuitas Investments LLC Raises Position in NextCure, Inc. (NASDAQ:NXTC)

Acuitas Investments LLC lifted its stake in shares of NextCure, Inc. (NASDAQ:NXTC) by 30.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 372,799 shares of the company’s stock after buying an additional 85,982 shares during the quarter. Acuitas Investments LLC owned 1.34% of NextCure worth $425,000 as of its most recent filing with the SEC.

NextCure Trading Up 6.2 %

Shares of NASDAQ:NXTC traded up $0.08 during trading on Friday, hitting $1.37. 31,865 shares of the company’s stock were exchanged, compared to its average volume of 230,945. The firm has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.39. NextCure, Inc. has a 1-year low of $0.98 and a 1-year high of $2.57. The firm has a market cap of $38.22 million, a P/E ratio of -0.57 and a beta of 0.40.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.02. As a group, research analysts predict that NextCure, Inc. will post -1.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NXTC. HC Wainwright lifted their price target on shares of NextCure from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Needham & Company LLC reissued a “buy” rating and set a $4.00 price objective on shares of NextCure in a report on Wednesday, March 20th.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.